ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data

•

0 gefällt mir•162 views

Rhonda Greenapple

My article, entitled "ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data," was recently published in the August 2010 American Health & Drug Benefits journal.

ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data

ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data

Empfohlen

DiplopiaJitendra Ingole

$View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...$ $View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...$

View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...Rhonda Greenapple

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...Rhonda Greenapple

First Word Pharma View Points Commercial Prospects In The Obesity Market ...

First Word Pharma View Points Commercial Prospects In The Obesity Market ...

First Word Pharma View Points Commercial Prospects In The Obesity Market ...Rhonda Greenapple

Analysis: Drug Costs Become Bigger Issue In Cancer Care

Analysis: Drug Costs Become Bigger Issue In Cancer Care

Analysis: Drug Costs Become Bigger Issue In Cancer CareRhonda Greenapple

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesRhonda Greenapple

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Rhonda Greenapple

$Payers likely to throw up hurdles to Pfizer\'s new RA drug$ $Payers likely to throw up hurdles to Pfizer\'s new RA drug$

Payers likely to throw up hurdles to Pfizer\'s new RA drugRhonda Greenapple

Empfohlen

DiplopiaJitendra Ingole

$View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...$ $View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...$

View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval ...Rhonda Greenapple

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...

AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care D...Rhonda Greenapple

First Word Pharma View Points Commercial Prospects In The Obesity Market ...

First Word Pharma View Points Commercial Prospects In The Obesity Market ...

First Word Pharma View Points Commercial Prospects In The Obesity Market ...Rhonda Greenapple

Analysis: Drug Costs Become Bigger Issue In Cancer Care

Analysis: Drug Costs Become Bigger Issue In Cancer Care

Analysis: Drug Costs Become Bigger Issue In Cancer CareRhonda Greenapple

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies

Looking beyond Plavix for evidence of Lipitor-type post-expiry strategiesRhonda Greenapple

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...

Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry ...Rhonda Greenapple

$Payers likely to throw up hurdles to Pfizer\'s new RA drug$ $Payers likely to throw up hurdles to Pfizer\'s new RA drug$

Payers likely to throw up hurdles to Pfizer\'s new RA drugRhonda Greenapple

$How Payers View Pfizer\'s Rheumatoid Arthritis Pill$ $How Payers View Pfizer\'s Rheumatoid Arthritis Pill$

How Payers View Pfizer\'s Rheumatoid Arthritis PillRhonda Greenapple

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetRhonda Greenapple

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkRhonda Greenapple

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Rhonda Greenapple

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsRhonda Greenapple

Vbcc Aco Article

Vbcc Aco Article

Vbcc Aco ArticleRhonda Greenapple

$Obesity: Effective Treatment Requires Change in Payers\' Perspective$ $Obesity: Effective Treatment Requires Change in Payers\' Perspective$

Obesity: Effective Treatment Requires Change in Payers\' PerspectiveRhonda Greenapple

Roadmap to reimbursement and access

Roadmap to reimbursement and access

Roadmap to reimbursement and accessRhonda Greenapple

Weitere ähnliche Inhalte

Mehr von Rhonda Greenapple

$How Payers View Pfizer\'s Rheumatoid Arthritis Pill$ $How Payers View Pfizer\'s Rheumatoid Arthritis Pill$

How Payers View Pfizer\'s Rheumatoid Arthritis PillRhonda Greenapple

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure BetRhonda Greenapple

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam DunkRhonda Greenapple

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011Rhonda Greenapple

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 DiabetsRhonda Greenapple

Vbcc Aco Article

Vbcc Aco Article

Vbcc Aco ArticleRhonda Greenapple

$Obesity: Effective Treatment Requires Change in Payers\' Perspective$ $Obesity: Effective Treatment Requires Change in Payers\' Perspective$

Obesity: Effective Treatment Requires Change in Payers\' PerspectiveRhonda Greenapple

Roadmap to reimbursement and access

Roadmap to reimbursement and access

Roadmap to reimbursement and accessRhonda Greenapple

Mehr von Rhonda Greenapple (8)

$How Payers View Pfizer\'s Rheumatoid Arthritis Pill$ $How Payers View Pfizer\'s Rheumatoid Arthritis Pill$

How Payers View Pfizer\'s Rheumatoid Arthritis Pill

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets

Vbcc Aco Article

Vbcc Aco Article

Vbcc Aco Article

$Obesity: Effective Treatment Requires Change in Payers\' Perspective$ $Obesity: Effective Treatment Requires Change in Payers\' Perspective$

Obesity: Effective Treatment Requires Change in Payers\' Perspective

Roadmap to reimbursement and access

Roadmap to reimbursement and access

Roadmap to reimbursement and access